Moderna’s coronavirus vaccine is safe and effective in children aged 12-17, the company announced on Tuesday morning.
The company’s study, which included 3,700 participants in the age range, found that no patient who received two doses of the vaccine got the coronavirus. Additionally, it showed an efficacy of 93% after one dose.
The company also found no “significant” safety concerns regarding the trial, and they plan on submitting a request for authorization early next month.
CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER
“We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents. It is particularly exciting to see that the Moderna COVID-19 vaccine can prevent SARS-CoV-2 infection,” Stephane Bancel, CEO of Moderna, said. “We will submit these results to the U.S. FDA and regulators globally in early June and request authorization. We remain committed to doing our part to help end the COVID-19 pandemic.”
